Physician profile
Miranda Akers
NPI 1275138612
$939.25
in general payments reported to CMS, 2019-2025
21 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $178 · 2023: $175 · 2024: $207 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.67 |
| Education | $156.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $163.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $136.26 | 2023-2024 | Sotyktu |
| Revance Therapeutics, INC. | $80.64 | 2025 | Daxxify |
| Sanofi-Aventis U.S. LLC | $72.00 | 2024 | |
| Ucb, INC. | $44.87 | 2024 | Bimzelx |
| Pfizer INC. | $44.75 | 2025 | |
| Abbvie INC. | $44.56 | 2023-2025 | Skyrizi |
| Bayer Healthcare Pharmaceuticals INC. | $41.87 | 2025 | |
| Glaxosmithkline, LLC. | $38.46 | 2025 | Ojjaara, Blenrep |
| Amgen INC. | $37.95 | 2023-2024 | Otezla |
| Daiichi Sankyo INC. | $37.85 | 2025 | Datroway |
| Novartis Pharmaceuticals Corporation | $32.80 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $23.26 | 2023 | Dupixent |
| Exelixis INC. | $19.97 | 2025 | Cabometyx |
| Genzyme Corporation | $19.19 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $18.60 | 2025 | Vyloy |
| Janssen Biotech, INC. | $18.25 | 2025 | Darzalex, Tecvayli, Talvey |
| Sobi, INC | $18.18 | 2025 | |
| Iovance Biotherapeutics, INC. | $16.40 | 2025 | Amtagvi |
| Genentech USA, INC. | $15.80 | 2023 | Xolair |
| Lilly USA, LLC | $14.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Akers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.